marketcaparena
Search

    LGVN

    Longeveron Inc.

    Company overview

    Market capitalization
    $81.91M
    Employees
    38
    Latest publication
    2026-09-29
    About Longeveron Inc.

    Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue287,000USD398,000USD365,000USD137,000USD316,000USD381,000USD2,392,000USD773,000USD
    Cost Of Revenue105,000USD134,000USD108,000USD12,000USD170,000USD106,000USD—91,000USD
    Gross Profit182,000USD264,000USD257,000USD125,000USD146,000USD275,000USD1,884,000USD682,000USD
    Research Development3,194,000USD2,319,000USD2,720,000USD3,852,000USD2,954,000USD2,515,000USD8,137,000USD2,206,000USD
    Selling General Administrative3,159,000USD2,720,000USD2,936,000USD3,583,000USD2,589,000USD2,941,000USD—3,125,000USD
    General And Administrative Expenses3,159,000USD2,720,000USD—3,583,000USD2,589,000USD2,941,000USD—3,125,000USD
    Total Operating Expenses6,353,000USD5,039,000USD5,656,000USD7,435,000USD5,543,000USD5,456,000USD18,406,000USD5,331,000USD
    Operating Income-6,171,000USD-4,775,000USD-5,399,000USD-7,310,000USD-5,397,000USD-5,181,000USD—-4,649,000USD
    Total Other Income Expense Net98,000USD39,000USD-45,000USD89,000USD369,000USD170,000USD—230,000USD
    Income Before Tax-6,073,000USD-4,736,000USD-5,444,000USD-7,221,000USD-5,028,000USD-5,011,000USD—-4,419,000USD
    Income Tax Expense0USD0USD—0USD0USD0USD—0USD
    Net Income-6,073,000USD-4,736,000USD-5,444,000USD-7,221,000USD-5,028,000USD-5,011,000USD-15,973,000USD-4,419,000USD
    Net Income From Continuing Ops——-5,444,000USD—————
    Ebit——-5,399,000USD—————
    Ebitda——-5,121,000USD—————
    Depreciation And Amortization——278,000USD—————
    Reconciled Depreciation——278,000USD—————
    Net Income Applicable To Common Shares———-7,221,000USD-5,028,000USD——-4,568,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosurePreliminaryDisclosureDeterministicFinal

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Revenue1,199,000USD2,392,000USD709,000USD1,222,000USD1,306,000USD5,629,000USD5,629,531USD2,134,775USD
    Cost Of Revenue396,000USD508,000USD488,000USD725,000USD716,000USD3,803,000USD3,803,261USD1,454,126USD
    Gross Profit803,000USD1,884,000USD221,000USD497,000USD590,000USD1,826,000USD1,826,270USD680,649USD
    Research Development12,041,000USD8,137,000USD9,066,000USD9,370,000USD7,092,000USD2,674,000USD2,674,370USD3,875,842USD
    Selling General Administrative12,049,000USD10,269,000USD11,401,000USD8,119,000USD10,734,000USD2,731,000USD2,731,174USD3,117,260USD
    General And Administrative Expenses12,049,000USD10,269,000USD11,401,000USD8,119,000USD10,734,000USD———
    Total Operating Expenses24,090,000USD18,406,000USD21,250,000USD18,540,000USD18,046,000USD5,604,000USD5,604,547USD7,041,266USD
    Operating Income-23,287,000USD-16,522,000USD-21,029,000USD-18,043,000USD-17,456,000USD-3,778,000USD-3,778,277USD-6,360,617USD
    Total Other Income Expense Net583,000USD549,000USD-384,000USD-792,000USD411,000USD57,000USD57,469USD23,821USD
    Income Before Tax-22,704,000USD-15,973,000USD-21,413,000USD——-3,721,000USD-3,720,808USD-6,336,796USD
    Income Tax Expense0USD0USD0USD——70,412USD35,630USD23,821USD
    Net Income-22,704,000USD-15,973,000USD-21,413,000USD-18,835,000USD-17,045,000USD-3,721,000USD-3,720,808USD-6,336,796USD
    Net Income Applicable To Common Shares-22,704,000USD-24,623,000USD-22,211,000USD——-3,720,808USD-2,959,877USD-6,336,796USD
    Selling And Marketing Expenses——783,000USD1,051,000USD220,000USD199,000USD199,003USD48,164USD
    Interest Expense———1,398,000USD4,000USD6,541USD169USD0USD
    Labor And Related Expense————600,000USD———
    Interest Income—————139USD2,937USD23,821USD
    Net Interest Income—————-6,402USD2,768USD23,821USD
    Net Income From Continuing Ops—————-3,720,808USD-2,959,877USD-6,336,796USD
    Ebit—————-3,714,000USD-3,714,267USD-6,336,796USD
    Ebitda—————-2,929,000USD-2,945,431USD-5,591,022USD
    Depreciation And Amortization—————785,000USD768,836USD745,774USD
    Reconciled Depreciation—————785,437USD768,836USD745,774USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets15,487,000USD21,210,000USD10,261,000USD15,557,000USD16,749,000USD20,848,000USD25,558,000USD29,909,000USD
    Cash And Equivalents10,077,000USD15,758,000USD4,661,000USD9,244,000USD10,334,000USD14,327,000USD19,232,000USD22,778,000USD
    Total Current Assets11,323,000USD16,855,000USD5,451,000USD10,340,000USD11,269,000USD15,275,000USD19,624,000USD23,767,000USD
    Other Current Assets1,181,000USD1,029,000USD686,000USD1,044,000USD904,000USD919,000USD308,000USD609,000USD
    Other Non Current Assets12,000USD18,000USD176,000USD178,000USD200,000USD201,000USD202,000USD203,000USD
    Total Liabilities5,085,000USD5,183,000USD4,586,000USD5,591,000USD4,093,000USD3,690,000USD3,671,000USD4,282,000USD
    Total Current Liabilities4,307,000USD4,345,000USD4,087,000USD4,940,000USD3,284,000USD2,724,000USD2,582,000USD3,100,000USD
    Other Current Liabilities400,000USD341,000USD2,969,000USD3,173,000USD1,905,000USD1,647,000USD1,820,000USD1,479,000USD
    Other Non Current Liabilities0USD0USD330,000USD315,000USD308,000USD302,000USD265,000USD199,000USD
    Total Stockholder Equity10,402,000USD16,027,000USD5,675,000USD9,966,000USD12,656,000USD17,158,000USD21,887,000USD25,627,000USD
    Total Equity Including Noncontrolling Interest10,402,000USD16,027,000USD5,675,000USD9,966,000USD12,656,000USD17,158,000USD21,887,000USD25,627,000USD
    Deferred Revenue40,000USD102,000USD40,000USD40,000USD40,000USD79,000USD40,000USD118,000USD
    Net Receivables65,000USD68,000USD104,000USD52,000USD31,000USD29,000USD84,000USD380,000USD
    Property Plant Equipment Net1,950,000USD2,099,000USD2,349,000USD2,730,000USD2,959,000USD3,081,000USD3,331,000USD3,592,000USD
    Intangible Assets2,202,000USD2,238,000USD2,285,000USD2,309,000USD2,321,000USD2,291,000USD2,401,000USD2,347,000USD
    Accounts Payable633,000USD293,000USD423,000USD1,080,000USD700,000USD367,000USD99,000USD887,000USD
    Short Term Debt581,000USD688,000USD655,000USD647,000USD639,000USD631,000USD623,000USD616,000USD
    Retained Earnings-143,120,000USD-137,047,000USD-132,311,000USD-126,867,000USD-119,646,000USD-114,618,000USD-109,607,000USD-105,525,000USD
    Cash And Short Term Investments—————14,327,000USD19,232,000USD22,778,000USD
    Short Term Investments—————0USD0USD0USD
    Accumulated Other Comprehensive Income———————-1,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinal

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets10,261,000USD25,558,000USD12,078,000USD27,413,000USD42,766,000USD9,240,000USD10,584,415USD10,521,702USD
    Cash And Equivalents4,661,000USD19,232,000USD4,949,000USD10,503,000USD25,658,000USD———
    Total Current Assets5,451,000USD19,624,000USD5,848,000USD20,280,000USD35,380,000USD1,849,000USD2,371,098USD4,164,787USD
    Other Current Assets686,000USD308,000USD376,000USD404,000USD282,000USD613,000USD53,766USD133,059USD
    Other Non Current Assets176,000USD202,000USD193,000USD—————
    Total Liabilities4,586,000USD3,671,000USD5,337,000USD6,910,000USD5,313,000USD———
    Total Current Liabilities4,087,000USD2,582,000USD3,889,000USD4,869,000USD2,708,000USD3,830,000USD2,486,877USD1,863,374USD
    Other Current Liabilities2,969,000USD1,820,000USD2,152,000USD650,000USD1,327,000USD———
    Other Non Current Liabilities330,000USD265,000USD——————
    Total Stockholder Equity5,675,000USD21,887,000USD6,741,000USD20,503,000USD37,453,000USD1,957,000USD4,445,042USD6,814,277USD
    Total Equity Including Noncontrolling Interest5,675,000USD21,887,000USD6,741,000USD20,503,000USD37,453,000USD———
    Deferred Revenue40,000USD40,000USD506,000USD506,000USD————
    Net Receivables104,000USD84,000USD111,000USD218,000USD—420,000USD451,458USD0USD
    Property Plant Equipment Net2,349,000USD3,331,000USD3,750,000USD4,480,000USD3,062,000USD5,667,000USD6,482,368USD4,760,515USD
    Intangible Assets2,285,000USD2,401,000USD2,287,000USD2,409,000USD2,334,000USD1,547,000USD1,480,056USD1,345,507USD
    Accounts Payable423,000USD99,000USD638,000USD—645,000USD1,590,000USD1,154,732USD1,205,426USD
    Short Term Debt655,000USD623,000USD593,000USD564,000USD537,000USD688,000USD485,785USD—
    Retained Earnings-132,311,000USD-109,607,000USD-84,984,000USD-62,773,000USD-43,938,000USD-26,892,861USD——
    Cash And Short Term Investments—19,232,000USD5,361,000USD—9,962,698USD816,000USD1,865,874USD4,031,728USD
    Short Term Investments—0USD412,000USD—9,471,000USD0USD——
    Common Stock———6,000USD5,000USD1,957,000USD4,595,042USD7,114,277USD
    Accumulated Other Comprehensive Income———-357,000USD—-99,999USD-150,000USD-1,393,994USD
    Total Liab—————7,283,000USD6,139,373USD3,707,425USD
    Other Current Liab—————1,542,000USD304,567USD252,948USD
    Capital Stock—————1,957,000USD——
    Other Assets—————2,246USD250,893USD250,893USD
    Cash—————816,000USD1,865,874USD4,031,728USD
    Current Deferred Revenue—————10,000USD541,793USD405,000USD
    Net Debt—————3,325,000USD2,272,407USD-4,031,728USD
    Short Long Term Debt—————177,269USD——
    Short Long Term Debt Total—————4,141,000USD4,138,281USD—
    Long Term Debt—————311,511USD——
    Property Plant Equipment Gross—————5,666,328USD6,482,368USD4,760,515USD
    Common Stock Shares Outstanding—————1,686,082shares1,601,746shares1,590,684shares
    Non Current Assets Total—————7,391,000USD8,213,317USD6,356,915USD
    Non Current Liabilities Total—————3,453,000USD3,652,496USD1,844,051USD
    Non Currrent Assets Other—————177,000USD250,893USD250,893USD
    Net Working Capital—————-1,980,172USD-115,779USD2,301,413USD
    Net Tangible Assets—————409,568USD2,964,986USD5,468,770USD
    Unclassified Non Current Liabilities—————3,141,489USD3,652,496USD—
    Unclassified Equity—————25,035,860USD—1,093,994USD
    Other Liab———————1,844,051USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USDQ3 20232023-09-30 · USDQ2 20232023-06-30 · USDQ3 20222022-09-30 · USD
    Depreciation400,000USD600,000USD400,000USD716,000USD400,000USD500,000USD400,000USD500,000USD
    Stock Based Compensation752,000USD1,301,000USD853,000USD1,938,000USD525,000USD——1,691,000USD
    Change To Account Receivables39,000USD———————
    Change To Liabilities-120,000USD2,532,000USD876,000USD-227,000USD-452,000USD-99,000USD607,000USD-642,000USD
    Change In Working Capital-411,000USD320,000USD50,000USD-183,000USD-466,000USD-1,486,000USD-1,164,000USD-256,000USD
    Operating Cash Flow-10,023,000USD-13,349,000USD-8,294,000USD-10,495,000USD-7,652,000USD-15,005,000USD-10,449,000USD-11,661,000USD
    Capital Expenditures-103,000USD-245,000USD-188,000USD-642,000USD-212,000USD-137,000USD-134,000USD-503,000USD
    Unclassified Investing Cash Flow-20,000USD-286,000USD-225,000USD-227,000USD-177,000USD6,759,000USD2,930,000USD396,000USD
    Investing Cash Flow-123,000USD-531,000USD-413,000USD-517,000USD-39,000USD6,622,000USD2,796,000USD-107,000USD
    Financing Cash Flow15,562,000USD3,892,000USD-191,000USD28,841,000USD15,117,000USD-153,000USD-103,000USD-316,000USD
    Change In Cash5,416,000USD-9,988,000USD-8,898,000USD17,829,000USD7,426,000USD-8,536,000USD-7,756,000USD-12,084,000USD
    End Cash Flow10,077,000USD9,244,000USD10,334,000USD22,778,000USD12,375,000USD1,967,000USD2,747,000USD13,574,000USD
    Net Investments———352,000USD350,000USD———
    Net Common Stock Issuance—————-153,000USD-103,000USD-316,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Depreciation200,000USD278,000USD264,000USD263,000USD200,000USD242,000USD235,000USD229,000USD
    Stock Based Compensation379,000USD376,000USD448,000USD513,000USD340,000USD2,328,000USD1,400,000USD200,000USD
    Change To Account Receivables36,000USD-52,000USD-21,000USD-2,000USD—296,000USD-162,000USD-40,000USD
    Change To Liabilities-460,000USD———132,000USD———
    Change In Working Capital-547,000USD-603,000USD1,074,000USD655,000USD-266,000USD943,000USD-78,000USD-376,000USD
    Operating Cash Flow-4,370,000USD———-4,697,000USD———
    Capital Expenditures0USD-64,000USD-57,000USD-161,000USD-27,000USD-13,000USD-430,000USD-196,000USD
    Unclassified Investing Cash Flow-20,000USD———-123,000USD———
    Investing Cash Flow-20,000USD———-150,000USD———
    Financing Cash Flow15,487,000USD———-58,000USD———
    Change In Cash11,097,000USD-4,583,000USD-1,090,000USD-3,993,000USD-4,905,000USD-3,546,000USD10,403,000USD10,435,000USD
    End Cash Flow15,758,000USD———14,327,000USD———
    Net Income—-5,444,000USD-7,221,000USD-5,028,000USD—-4,081,000USD-4,419,000USD-3,413,000USD
    Other Non Cash Items—97,000USD828,000USD655,000USD—-2,805,000USD19,000USD-1,206,000USD
    Total Cash From Operating Activities—-5,296,000USD-5,055,000USD-3,597,000USD—-3,373,000USD-2,843,000USD-4,566,000USD
    Free Cash Flow—-5,360,000USD-5,112,000USD-3,758,000USD—-3,386,000USD-3,273,000USD-4,762,000USD
    Investments—0USD-118,000USD-263,000USD—-123,000USD-478,000USD-53,000USD
    Total Cashflows From Investing Activities—-64,000USD-118,000USD-263,000USD—-123,000USD-478,000USD-53,000USD
    Total Cash From Financing Activities—777,000USD4,083,000USD-133,000USD—-50,000USD13,724,000USD15,054,000USD
    Sale Purchase Of Stock—-58,000USD-61,000USD-133,000USD—-53,000USD-270,000USD-6,000USD
    Issuance Of Capital Stock—836,000USD4,144,000USD0USD—0USD8,144,000USD—
    Begin Period Cash Flow—9,244,000USD10,334,000USD14,327,000USD—22,778,000USD12,375,000USD1,940,000USD
    End Period Cash Flow—4,661,000USD9,244,000USD10,334,000USD—19,232,000USD22,778,000USD12,375,000USD
    Other Cashflows From Investing Activities—349,000USD-61,000USD-263,000USD—-110,000USD-48,000USD143,000USD
    Other Cashflows From Financing Activities—-59,000USD4,144,000USD-133,000USD—3,000USD13,994,000USD15,060,000USD
    Dividends Paid——————-8,650,000USD—
    Unclassified Financing Cash Flow——————8,650,000USD—
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Depreciation800,000USD700,000USD700,000USD——785,437USD768,836USD745,774USD
    Stock Based Compensation1,677,000USD2,328,000USD2,032,000USD170,000USD1,297,000USD83,000USD136,846USD423,866USD
    Change To Liabilities1,686,000USD-607,000USD389,000USD429,000USD-1,159,000USD-400,858USD-120,128USD104,414USD
    Change In Working Capital38,000USD-682,000USD-1,034,000USD969,000USD-1,176,000USD488,634USD-216,483USD-11,216USD
    Operating Cash Flow-18,645,000USD-13,868,000USD-19,002,000USD-13,969,000USD-9,636,000USD———
    Capital Expenditures-245,000USD-655,000USD-301,000USD-569,000USD-330,000USD-261,500USD-37,573USD-211,684USD
    Net Investments0USD352,000USD8,880,000USD—————
    Unclassified Investing Cash Flow-350,000USD-337,000USD-393,000USD-108,000USD-10,366,000USD———
    Investing Cash Flow-595,000USD-640,000USD8,186,000USD-677,000USD-10,696,000USD———
    Financing Cash Flow4,669,000USD28,791,000USD5,262,000USD-509,000USD45,174,000USD———
    Change In Cash-14,571,000USD14,283,000USD-5,554,000USD-15,155,000USD24,842,000USD-1,050,074USD-2,165,854USD-4,035,056USD
    End Cash Flow4,661,000USD19,232,000USD4,949,000USD10,503,000USD25,658,000USD———
    Net Common Stock Issuance——-174,000USD-304,000USD-451,000USD———
    Unclassified Financing Cash Flow——5,436,000USD-205,000USD45,625,000USD———
    Net Income—————-3,720,808USD-2,959,877USD-6,336,796USD
    Other Non Cash Items—————-167USD-120,128USD1,903,619USD
    Change To Account Receivables—————30,806USD-451,458USD24,881USD
    Change To Inventory—————-30,806USD86,783USD—
    Total Cash From Operating Activities—————-2,363,904USD-2,390,806USD-5,178,372USD
    Free Cash Flow—————-2,625,404USD-2,428,379USD-5,390,056USD
    Investments—————-261,500USD-125,048USD-211,684USD
    Total Cashflows From Investing Activities—————-261,500USD-125,047USD-211,684USD
    Net Borrowings—————488,780USD488,780USD488,780USD
    Total Cash From Financing Activities—————1,575,330USD350,000USD1,355,000USD
    Issuance Of Capital Stock—————1,100,000USD——
    Begin Period Cash Flow—————1,865,874USD4,031,728USD8,066,784USD
    End Period Cash Flow—————815,800USD1,865,874USD4,031,728USD
    Other Cashflows From Investing Activities—————-130,000USD-87,474USD-115,721USD
    Other Cashflows From Financing Activities—————-12,670USD350,000USD1,355,000USD
    Unclassified Operating Cash Flow———————-1,903,619USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2026Quarterly · 2026-03-31ProductClinical Trial Revenue378,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductContract Manufacturing Revenue20,000USDDisclosure
    Q4 2025Quarterly · 2025-12-31ProductClinical Trial Revenue303,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductContract Manufacturing Lease Revenue5,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductContract Manufacturing Revenue57,000USDLegacy provider
    FY 2025Yearly · 2025-12-31ProductClinical Trial Revenue954,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductContract Manufacturing Lease Revenue23,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductContract Manufacturing Revenue222,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductClinical Trial Revenue94,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductContract Manufacturing Lease Revenue6,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductContract Manufacturing Revenue37,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30ProductClinical Trial Revenue298,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30ProductContract Manufacturing Lease Revenue6,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30ProductContract Manufacturing Revenue12,000USDDisclosure
    Q1 2025Quarterly · 2025-03-31ProductClinical Trial Revenue259,000USDDisclosure
    Q1 2025Quarterly · 2025-03-31ProductContract Manufacturing Lease Revenue6,000USDDisclosure
    Q1 2025Quarterly · 2025-03-31ProductContract Manufacturing Revenue116,000USDDisclosure
    Q4 2024Quarterly · 2024-12-31ProductClinical Trial Revenue390,000USDDisclosure
    Q4 2024Quarterly · 2024-12-31ProductContract Manufacturing Lease Revenue126,000USDDisclosure
    Q4 2024Quarterly · 2024-12-31ProductContract Manufacturing Revenue87,000USDDisclosure
    FY 2024Yearly · 2024-12-31ProductClinical Trial Revenue1,402,000USDDisclosure
    FY 2024Yearly · 2024-12-31ProductContract Manufacturing Lease Revenue503,000USDDisclosure
    FY 2024Yearly · 2024-12-31ProductContract Manufacturing Revenue487,000USDDisclosure
    FY 2022Yearly · 2022-12-31ProductClinical Trial Revenue940,000USDDisclosure
    FY 2022Yearly · 2022-12-31ProductGrant Revenue — MSCRFTEDCOGrants118,000USDDisclosure
    FY 2022Yearly · 2022-12-31ProductNational Institute Of Health Grant164,000USDDisclosure
    Q1 2021Quarterly · 2021-03-31ProductAlzheimers Association Grant170,000USDDisclosure
    Q1 2021Quarterly · 2021-03-31ProductClinical Trial Revenue165,000USDDisclosure
    Q1 2021Quarterly · 2021-03-31ProductMaryland TEDCOGrant41,000USDDisclosure

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.